Skip to main content

Table 3 Baseline clinical and treatment characteristics of patients under follow-up at 20.10.2008, by risk of transmission (N = 8,213)

From: Epidemiological composition, clinical and treatment characteristics of the patient cohort of the german competence network for HIV/AIDS

  Risk of transmission
  Hetero HPL IVDU MSM
Proportions of risk of transmission (%)1 18.4 5.2 7.0 63.0
Current CDC-stage (%)     
   A 31.1 40.7 23.1 28.2
   B 43.4 33.4 51.1 46.4
   C 25.5 25.9 25.8 25.4
Prevalence of Hepatitis-Co-Infections (%, N = 6,279)2     
   Hepatitis B 3.4 7.3 1.6 5.5
   Hepatitis C 11.4 4.5 71.2 6.5
   Hepatits B + C 1.0 0.3 6.3 0.7
Mean CD4 cell count/μl at date of first documentation (IQR) 327
(123-479)
298
(109-400)
370
(170-500)
387
(179-536)
Mean CD4 cell count/μl of currently treated patients (IQR) 533
(331-670)
490
(334-630)
480
(266-591)
553
(362-698)
Number of treated patients documented as assured therapy-naïve at start of documentation (N = 3,230; %)3 655
(20.3)
222
(6.9)
213
(6.6)
2140
(66.2)
Mean CD4 cell count/μl at start of initial ART, (IQR) 288
(138-403)
258
(110-375)
319
(170-420)
301
(170-394)
Mean HIV RNA at start of initial ART, mean log copies/ml (IQR) 4.0
(3.0-5.1)
4.1
(3.2-5.1)
3.8
(2.7-5.0)
4.3
(3.5-5.2)
Proportion of patients having CD4 cell count/μl < 150 at start of initial ART (%) 26.0 33.6 20.6 20.5
  1. 1Other risks of transmission low frequent and not showed, multiple answers possible.
  2. 2N reduced to 6,279; for 1,944 patients no data on tests for Hepatitis B/C available; prevalences including acute and chronic Hepatitis as well as state after Hepatitis B/C (tested serologically).
  3. 3Only patients being documented as assured therapy-naïve at start of documentation were eligible for analyses regarding start of initial ART.